WALTHAM, Mass., Feb 27, 2013 (Menafn - GLOBE NEWSWIRE via COMTEX) --BG Medicine, Inc. BGMD, a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today the publication of two studies demonstrating the clinical utility of repeated galectin-3 testing as a tool in the assessment of patients with heart failure.

DUBLIN and LEXINGTON, Mass., Feb 26, 2013 (BUSINESS WIRE) -- Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc. today announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert's deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323.

500th XF Data Reference in Elsevier: Cell Stem Cell

Billerica, MA, February 22, 2013 – Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism, announced a new milestone: the 500th journal reference including XF assay data. The paper, titled BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells, will be published in the March 7, 2013 issue of the journal Cell Stem Cell.

WALTHAM, MA – February 20, 2013 – Novomer, Inc., a sustainable materials company pioneering a family of high-performance polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), has announced the world's first large-scale manufacturing run of polypropylene carbonate (PPC) polyol, producing over seven tons of finished product. The PPC polyol was scaled up and produced with Albemarle at their Orangeburg, South Carolina manufacturing facility using existing Albemarle equipment, which was modified for PPC polyol production.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Preclinical Data Showing Benefits of Macrocycle Discovery Platform in Identifying First-in-Class Oral IL-17 Antagonists Presented At Molecular Med Tri Con 2013 Conference

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Receptos, Inc. announced today that Graham Cooper has been appointed Chief Financial Officer. Mr.

Watertown, MA – February 12, 2013 – Tetraphase Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering.

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone under its licensing agreement with Avanir Pharmaceuticals, Inc. for the development of AVP-786 (also known as CTP-786 or deuterated dextromethorphan).